Companies › Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Genitourinary, Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nedosiran Sodium L-lactate dehydrogenase A chain mRNA RNAi inhibitor | LDHA | Phase 3 | Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 1 | Apr 2030 |
| DCR-PDL1 PDL1 inhibitor delivered via RNAi | PDCD1LG1 | Phase 1 | Solid Tumors, Adult | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06504368 | DCR-PDL1 | Phase 1 | Solid Tumors, Adult | Oncology | Dec 2027 |
| NCT04042402 | Nedosiran Sodium | Phase 3 | Primary Hyperoxaluria Type 1 (PH1) | Genitourinary | Apr 2030 |
| NCT04580420 | Nedosiran Sodium | Phase 2 | Primary Hyperoxaluria Type 1 | Genitourinary | Dec 2031 |
ImmunityBio Chia Tai Tianqing Pharmaceutical Group Pfizer MediLink Therapeutics (Suzhou)
Hope Biosciences Shenzhen Kangzhe Biotechnology Norroy Bioscience Everest Medicines (China) Biocity Biopharmaceutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.